Introduction
Anxiety is the most prevalent psychiatric disorder affecting one in four adults across their lifetime (Kessler et al., 2005) and over 10% of individuals in later-life (Ritchie et al., 2004) .
Female gender is a risk factor for later-life anxiety (Kessler et al., 2005) , and evidence suggests the involvement of estrogen. Estrogen can influence the levels of neurotransmitters which have been directly implicated in anxiety, such as γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the brain, and serotonin (5-HT) (Zinder and Dar, 1999) . Estrogen upregulates GABA receptor expression and ligand binding and regulates 5-HT1A receptor number and function, thus controlling the activity of serotonergic neurons. In vitro and in vivo experiments have shown that estrogen treatment increases basal and stimulated extracellular GABA concentrations and stimulates serotonergic activity (see for review (Birzniece et al., 2006) ).
Studies using murine models have also demonstrated estrogen's anxiolytic effects (Walf and Frye, 2006) .
Given the potential aetiological role of estrogen in anxiety, genes for the estrogen receptors (ERs) are obvious candidates implicated in this disorder. Indeed, studies in knock-out mice deficient in ESR1 or ESR2 genes support the involvement of these receptors in social recognition and anxiety (Walf and Frye, 2006) . Only a very small number of studies in humans however, have examined the possibility that genetic variations in the ERs may influence the risk of anxiety. A study of children and adolescents reported an association between ESR1 gene variants and anxiety-related traits (Prichard et al., 2002) , and ESR1 variants were recently associated with contamination obsessions and cleaning compulsions in young adult patients with obsessive-compulsive disorder (Alonso et al., 2011) . In terms of late-life anxiety, the Rotterdam study reported that ESR1 haplotypes consisting of the T and A alleles of rs2234693 and inserm-00619147, version 1 -5 Sep 2011 rs9340799 respectively were associated with an increased risk of global anxiety level in 1335 older women (Tiemeier et al., 2005) , however, to our knowledge, no subsequent study has sought to replicate these findings. Furthermore, prior studies have not examined ESR2, although evidence in mice suggests that ESR2 may be particularly important in modulating anxiety-like behavior (Walf and Frye, 2006) .
Our study aimed to replicate and further the Rotterdam study's findings, by investigating the association between the same ESR1 gene variants and the most common anxiety disorders in this elderly female population (generalized anxiety-disorder [GAD] and phobia). Three ESR2 polymorphisms were also examined. Furthermore, as older postmenopausal women have low endogenous estrogen levels, we also investigated whether the use of estrogen-containing hormone treatment (HT) could modify the association between ER variants and anxiety.
Method

Study Population
Data were obtained from the ESPRIT study of psychiatric disorders in community-dwelling elderly (Ritchie et al., 2004) . Eligible participants (aged at least 65 years and noninstitutionalised) were randomly selected from the electoral rolls in Montpellier, France. Of the people initially drawn at random, 27.3% did not participate. All procedures were carried out with the adequate understanding and written consent of the participants. The national ethics committee approved the study. Of the 1277 non-demented women recruited to the study, 185
were excluded from this analysis as they did not provide samples for genotyping analysis and/or
were not assessed for anxiety disorders. Table 1 shows the participant's characteristics.
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Anxiety disorders
A standardized psychiatric examination validated in the general population, the MiniInternational Neuropsychiatry Interview (MINI) (Sheehan et al., 1998) , was used for the diagnosis of current and past anxiety disorders (GAD, phobia, obsessive compulsive disorder, panic and post-traumatic stress disorder), according to DSM-IV criteria. Cases detected by the MINI were reviewed by a panel of psychiatrists to validate the initial diagnosis (Ritchie et al., 2004) . Current use of anxiolytics, validated by presentation of the prescription or medication, was also recorded.
Estrogen receptor polymorphisms
DNA extracted from white blood cells (Puregene kit, Qiagen, France) was stored at -80°C.
Genotyping was performed by Kbiosciences (Hoddesdon Herts, UK) using their competitive allele-specific PCR Single-Nucleotide Polymorphism (SNP) genotyping system (KASPar) which has an error rate of <0.3%. The ESR1 polymorphisms examined (rs2234693 and rs9340799),
were the same as those analyzed previously in the Rotterdam study (Tiemeier et al., 2005) . These 
Hormone treatment
Women stated whether they were current HT users, which was validated by presentation of the prescription or the medication itself. The majority of women (77.4%) used transdermal estradiol (16.5% unopposed, 22.6% combined with oral progesterone and 38.3% synthetic progestin), and 15.8% used oral estradiol (14.2% combined with synthetic progestin). Remaining women (6.8%) used other forms of HT. No women used ethinylestradiol or conjugated equine estradiol.
Statistical analysis
Genotype deviation from the Hardy-Weinberg equilibrium was evaluated with a χ 2 test, and pairwise linkage disequilibrium was estimated. Logistic regression models were used to estimate the association between the ER SNPs and anxiety disorders (GAD and phobia) assuming a dominant model (SAS v9.1, SAS Institute, Inc., NC). A first-order interaction between the SNPs and current HT use was also examined by including a product term in the models. When significant, subsequent analysis was stratified to determine independent group effects. Multivariate logistic models examined the potential confounding effect of age, education level, comorbidity, cognitive impairment or severe depression.
Results
Twenty-one percent of the population (n=232) had a current anxiety disorder. GAD and phobia were the most prevalent, affecting 87 (8%) and 155 (14.2%) of the women respectively. Only 18 women were diagnosed with comorbid phobia and GAD. Other anxiety disorders (i.e. panic,
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obsessive-compulsive disorder and post-traumatic stress disorder) were rare among this elderly population (n=8). Compared to non-anxious women, those with anxiety differed on a number of socio-demographic health and lifestyle characteristics ( Table 1 ).
All of the SNPs were in Hardy-Weinberg equilibrium. The ESR1 SNPs were in strong linkage disequilibrium (|D'|=0.98), as were the three ESR2 SNPs (|D'|>0.90 for all pairwise comparisons). Both ESR1 SNPs were significantly associated with the risk of phobia, with the variant alleles C and G of rs2234693 and rs9340799 respectively, decreasing the risk by over 30% (Table 2 conservative and increase the risk of a type 2 error, given that the tests were not independent (i.e.
the SNPs are in strong linkage disequilibrium).
Discussion
Animal studies suggest that estrogen is anxiolytic and these effects can be mediated by the ERs study has attempted to replicate these findings or to examine whether this could vary across anxiety disorders. We report here that in older women these same ESR1 gene variants were specifically associated with the risk of phobia, but current HT use could modify this association.
We also found that ESR2 rs1256049 was associated with the risk of GAD. Our study thus contributes important new findings to this field.
Although anxiety disorders often co-occur, there is a considerable degree of heterogeneity among the disorders and prior familial studies suggest a differential genetic component for GAD and phobia (Kendler et al., 1995) . A large twin study also found that GAD, panic and agoraphobia shared common genetic risk factors that were distinct from those of other specific phobias. Social phobia shared some genetic components with both groups ( . This is the first study to report that this gene-environment interaction may modify the risk of phobia. Despite reports that HT can improve psychological dysfunction, including anxiety symptoms in menopausal women, there is insufficient evidence to support a direct beneficial effect of HT in treating post-menopausal anxiety (Scali et al., 2009 ).
These current results however, suggest that genetically, some women may respond more beneficially to HT in terms of psychiatric outcomes.
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criteria, rather than just global anxiety like most previous studies. Our study is also one of the first to examine the association between ESR2 SNPs and anxiety. Study limitations include the possibility of population stratification which we could not control for because French law prohibits the collection of ethnic-related data. Genotype frequencies for both anxious and nonanxious participants were however, similar to those observed in Caucasian populations (Ioannidis et al., 2002; Rexrode et al., 2007) . Duplicate genotyping was not performed, however the genotyping system used does have a very low error rate (<0.3%). Replication of these results
in other large population-based studies is needed. 
